skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
FOREIGN
OSTI Identifier:
1259895
Resource Type:
Journal Article
Journal Name:
Scientific Reports
Additional Journal Information:
Journal Volume: 5; Journal Issue: 2015; Journal ID: ISSN 2045-2322
Publisher:
Nature Publishing Group
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Zhu, Xiaojie, Zhu, Yun, Ye, Sheng, Wang, Qian, Xu, Wei, Su, Shan, Sun, Zhiwu, Yu, Fei, Liu, Qi, Wang, Chao, Zhang, Tianhong, Zhang, Zhenqing, Zhang, Xiaoyan, Xu, Jianqing, Du, Lanying, Liu, Keliang, Lu, Lu, Zhang, Rongguang, and Jiang, Shibo. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. United States: N. p., 2015. Web. doi:10.1038/srep13028.
Zhu, Xiaojie, Zhu, Yun, Ye, Sheng, Wang, Qian, Xu, Wei, Su, Shan, Sun, Zhiwu, Yu, Fei, Liu, Qi, Wang, Chao, Zhang, Tianhong, Zhang, Zhenqing, Zhang, Xiaoyan, Xu, Jianqing, Du, Lanying, Liu, Keliang, Lu, Lu, Zhang, Rongguang, & Jiang, Shibo. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. United States. doi:10.1038/srep13028.
Zhu, Xiaojie, Zhu, Yun, Ye, Sheng, Wang, Qian, Xu, Wei, Su, Shan, Sun, Zhiwu, Yu, Fei, Liu, Qi, Wang, Chao, Zhang, Tianhong, Zhang, Zhenqing, Zhang, Xiaoyan, Xu, Jianqing, Du, Lanying, Liu, Keliang, Lu, Lu, Zhang, Rongguang, and Jiang, Shibo. Wed . "Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy". United States. doi:10.1038/srep13028.
@article{osti_1259895,
title = {Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy},
author = {Zhu, Xiaojie and Zhu, Yun and Ye, Sheng and Wang, Qian and Xu, Wei and Su, Shan and Sun, Zhiwu and Yu, Fei and Liu, Qi and Wang, Chao and Zhang, Tianhong and Zhang, Zhenqing and Zhang, Xiaoyan and Xu, Jianqing and Du, Lanying and Liu, Keliang and Lu, Lu and Zhang, Rongguang and Jiang, Shibo},
abstractNote = {},
doi = {10.1038/srep13028},
journal = {Scientific Reports},
issn = {2045-2322},
number = 2015,
volume = 5,
place = {United States},
year = {2015},
month = {8}
}

Works referenced in this record:

HIV Entry and Its Inhibition
journal, May 1998


A trimeric structural domain of the HIV-1 transmembrane glycoprotein
journal, December 1995

  • Lu, Min; Blacklow, Stephen C.; Kim, Peter S.
  • Nature Structural & Molecular Biology, Vol. 2, Issue 12
  • DOI: 10.1038/nsb1295-1075

Core Structure of gp41 from the HIV Envelope Glycoprotein
journal, April 1997


Atomic structure of a thermostable subdomain of HIV-1 gp41
journal, November 1997

  • Tan, K.; Liu, J. -h.; Wang, J. -h.
  • Proceedings of the National Academy of Sciences, Vol. 94, Issue 23
  • DOI: 10.1073/pnas.94.23.12303

Atomic structure of the ectodomain from HIV-1 gp41
journal, May 1997

  • Weissenhorn, W.; Dessen, A.; Harrison, S. C.
  • Nature, Vol. 387, Issue 6631
  • DOI: 10.1038/387426a0

HIV-1 inhibition by a peptide
journal, September 1993

  • Jiang, Shibo; Lin, Kang; Strick, Nathan
  • Nature, Vol. 365, Issue 6442
  • DOI: 10.1038/365113a0

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
journal, October 1994

  • Wild, C. T.; Shugars, D. C.; Greenwell, T. K.
  • Proceedings of the National Academy of Sciences, Vol. 91, Issue 21
  • DOI: 10.1073/pnas.91.21.9770

HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains: RELATION TO MECHANISMS OF ACTION OF ANTI-HIV PEPTIDES
journal, February 2007

  • Liu, Shuwen; Jing, Weiguo; Cheung, Byron
  • Journal of Biological Chemistry, Vol. 282, Issue 13
  • DOI: 10.1074/jbc.M609148200

Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis
journal, January 2006


Design of highly potent HIV fusion inhibitors based on artificial peptide sequences
journal, January 2012

  • Shi, Weiguo; Cai, Lifeng; Lu, Lu
  • Chemical Communications, Vol. 48, Issue 94
  • DOI: 10.1039/c2cc35973a

The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors
journal, August 2012

  • Chong, Huihui; Yao, Xue; Sun, Jianping
  • Journal of Biological Chemistry, Vol. 287, Issue 41
  • DOI: 10.1074/jbc.M112.390393

The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance
journal, June 2014

  • Chong, Huihui; Yao, Xue; Qiu, Zonglin
  • Journal of Antimicrobial Chemotherapy, Vol. 69, Issue 10
  • DOI: 10.1093/jac/dku183

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
journal, January 2014

  • Lu, Lu; Liu, Qi; Zhu, Yun
  • Nature Communications, Vol. 5, Issue 1
  • DOI: 10.1038/ncomms4067

Probing the paramyxovirus fusion (F) protein-refolding event from pre- to postfusion by oxidative footprinting
journal, June 2014

  • Poor, T. A.; Jones, L. M.; Sood, A.
  • Proceedings of the National Academy of Sciences, Vol. 111, Issue 25
  • DOI: 10.1073/pnas.1408983111

The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults
journal, July 2002

  • Kilby, J. Michael; Lalezari, Jacob P.; Eron, Joseph J.
  • AIDS Research and Human Retroviruses, Vol. 18, Issue 10
  • DOI: 10.1089/088922202760072294

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
journal, May 2003

  • Lalezari, Jacob P.; Henry, Keith; O'Hearn, Mary
  • New England Journal of Medicine, Vol. 348, Issue 22
  • DOI: 10.1056/NEJMoa035026

Pharmacokinetics of Enfuvirtide in Patients Treated in Typical Routine Clinical Settings
journal, January 2006


Cutaneous injection site reactions to long-term therapy with enfuvirtide
journal, February 2004

  • Maggi, P.
  • Journal of Antimicrobial Chemotherapy, Vol. 53, Issue 4
  • DOI: 10.1093/jac/dkh141

ADS-J1 Inhibits Human Immunodeficiency Virus Type 1 Entry by Interacting with the gp41 Pocket Region and Blocking Fusion-Active gp41 Core Formation
journal, September 2009

  • Wang, H.; Qi, Z.; Guo, A.
  • Antimicrobial Agents and Chemotherapy, Vol. 53, Issue 12
  • DOI: 10.1128/AAC.00670-09

ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer
journal, May 2014


Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
journal, May 2003

  • Lazzarin, Adriano; Clotet, Bonaventura; Cooper, David
  • New England Journal of Medicine, Vol. 348, Issue 22
  • DOI: 10.1056/NEJMoa035211

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
journal, July 2007

  • Dwyer, J. J.; Wilson, K. L.; Davison, D. K.
  • Proceedings of the National Academy of Sciences, Vol. 104, Issue 31
  • DOI: 10.1073/pnas.0701478104

Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy
journal, June 2002


Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
journal, November 1998

  • Kilby, J. Michael; Hopkins, Sam; Venetta, Thomas M.
  • Nature Medicine, Vol. 4, Issue 11
  • DOI: 10.1038/3293

Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor
journal, October 2004


Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41
journal, February 2005


Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
journal, December 1998

  • Chan, D. C.; Chutkowski, C. T.; Kim, P. S.
  • Proceedings of the National Academy of Sciences, Vol. 95, Issue 26
  • DOI: 10.1073/pnas.95.26.15613

Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants
journal, April 2008

  • Eggink, D.; Baldwin, C. E.; Deng, Y.
  • Journal of Virology, Vol. 82, Issue 13
  • DOI: 10.1128/JVI.00352-08

Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor
journal, February 2008

  • He, Yuxian; Xiao, Yonghong; Song, Haifeng
  • Journal of Biological Chemistry, Vol. 283, Issue 17
  • DOI: 10.1074/jbc.M800200200

Identification of minimal sequence for HIV-1 fusion inhibitors
journal, October 2008

  • Nishikawa, Hiroki; Oishi, Shinya; Fujita, Mizuno
  • Bioorganic & Medicinal Chemistry, Vol. 16, Issue 20
  • DOI: 10.1016/j.bmc.2008.09.018

Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity
journal, February 2008

  • Oishi, Shinya; Ito, Saori; Nishikawa, Hiroki
  • Journal of Medicinal Chemistry, Vol. 51, Issue 3
  • DOI: 10.1021/jm701109d

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
journal, October 2008

  • He, Y.; Cheng, J.; Lu, H.
  • Proceedings of the National Academy of Sciences, Vol. 105, Issue 42
  • DOI: 10.1073/pnas.0807335105

Phaser crystallographic software
journal, July 2007

  • McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.
  • Journal of Applied Crystallography, Vol. 40, Issue 4
  • DOI: 10.1107/S0021889807021206

Coot model-building tools for molecular graphics
journal, November 2004

  • Emsley, Paul; Cowtan, Kevin
  • Acta Crystallographica Section D Biological Crystallography, Vol. 60, Issue 12, p. 2126-2132
  • DOI: 10.1107/S0907444904019158

PHENIX: a comprehensive Python-based system for macromolecular structure solution
journal, January 2010

  • Adams, Paul D.; Afonine, Pavel V.; Bunkóczi, Gábor
  • Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2, p. 213-221
  • DOI: 10.1107/S0907444909052925

An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides
journal, June 2013

  • Tong, P.; Lu, Z.; Chen, X.
  • Journal of Antimicrobial Chemotherapy, Vol. 68, Issue 11
  • DOI: 10.1093/jac/dkt230

HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain
journal, December 2012


A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody
journal, June 1999


    Works referencing / citing this record:

    Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
    journal, May 2019

    • Dingens, Adam S.; Arenz, Dana; Overbaugh, Julie
    • Viruses, Vol. 11, Issue 5
    • DOI: 10.3390/v11050439